Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Dyne Therapeutics, Inc. (DYN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.96+0.17 (+1.93%)
At close: 04:00PM EDT
8.96 0.00 (0.00%)
After hours: 06:06PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close8.79
Open8.90
Bid8.59 x 800
Ask9.36 x 800
Day's Range8.65 - 9.07
52 Week Range8.04 - 15.60
Volume252,214
Avg. Volume419,569
Market Cap546.744M
Beta (5Y Monthly)0.16
PE Ratio (TTM)N/A
EPS (TTM)-3.55
Earnings DateNov 01, 2023 - Nov 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DYN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Dyne Therapeutics, Inc.
    Analyst Report: Xcel Energy Inc.Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy providers in the U.S. with half of its electricity sales coming from carbon-free energy.
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more
  • GlobeNewswire

    Dyne Therapeutics to Present at October Investor Conferences

    WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in October: Chardan’s 7th Annual Genetic Medicines Conference, fireside chat on Tuesday, October 3, 2023 at 11:00 a.m. ET in New York Jefferies Inaugural Biotech

  • GlobeNewswire

    Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

    - On Track to Report Initial Data from the Global, Multiple Ascending Dose Phase 1/2 ACHIEVE Clinical Trial in the Second Half of 2023 - WALTHAM, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for DYNE-101 for

  • Motley Fool

    Why Shares of Dyne Therapeutics Fell This Week

    The clinical-stage biotech's stock closed at $10.98 last week, then fell to as low as $8.57 this Friday, thanks to a number of insiders selling their shares. On Wednesday the company released six filings with the Securities and Exchange Commission (SEC), all showing selling by company executives on Tuesday. According to the filings, president and CEO Joshua Brumm sold 7,622 shares, chief operating officer Susanna High sold 1,635 shares, chief medical officer Wildon Farwell sold 1,707 shares, chief scientific officer Oxana Beskrovnaya sold 1,484 shares, chief business officer Jonathan McNeill sold 1,266 shares, and senior vice president Richard Scalzo sold 1,397 shares.

Advertisement
Advertisement